UBS Group AG - TETRAPHASE PHARMACEUTICALS I ownership

TETRAPHASE PHARMACEUTICALS I's ticker is TTPHXXXX and the CUSIP is 88165N105. A total of 102 filers reported holding TETRAPHASE PHARMACEUTICALS I in Q1 2016. The put-call ratio across all filers is 0.33 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of TETRAPHASE PHARMACEUTICALS I
ValueSharesWeighting
Q2 2019$175,000
-65.5%
364,785
-3.6%
0.00%
Q1 2019$507,000
+13.9%
378,308
-4.0%
0.00%
Q4 2018$445,000
-43.3%
394,141
+38.6%
0.00%
Q3 2018$785,000
+13.9%
284,351
+47.4%
0.00%
Q2 2018$689,000
-39.0%
192,871
-47.6%
0.00%
Q1 2018$1,130,000
+22500.0%
367,901
+56326.5%
0.00%
Q2 2017$5,000
-96.9%
652
-96.2%
0.00%
Q1 2017$159,000
+133.8%
17,269
+2.3%
0.00%
Q4 2016$68,000
+183.3%
16,882
+172.6%
0.00%
Q3 2016$24,000
+1100.0%
6,193
+1425.4%
0.00%
Q2 2016$2,000
-95.8%
406
-96.1%
0.00%
Q1 2016$48,000
-84.8%
10,500
-66.6%
0.00%
Q4 2015$316,000
+4.6%
31,435
-22.2%
0.00%
Q3 2015$302,000
-83.5%
40,411
+4.8%
0.00%
-100.0%
Q2 2015$1,830,000
+7.3%
38,567
-17.2%
0.00%0.0%
Q1 2015$1,706,000
+180.1%
46,553
+203.5%
0.00%
Q4 2014$609,00015,3380.00%
Other shareholders
TETRAPHASE PHARMACEUTICALS I shareholders Q1 2016
NameSharesValueWeighting ↓
HARVEY CAPITAL MANAGEMENT INC 354,300$7,068,0002.77%
Opaleye Management Inc. 169,700$3,385,515,0002.64%
Broadfin Capital, LLC 959,247$19,137,0002.01%
Novo Holdings A/S 900,000$17,955,0001.75%
Eventide Asset Management 300,900$6,003,0000.84%
EAM Investors, LLC 152,595$3,044,0000.62%
COLUMBIA PARTNERS L.L.C. INVESTMENT MANAGEMENT 497,858$9,932,0000.51%
Granite Point Capital Management, L.P. 40,000$798,0000.40%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 450,191$8,981,0000.33%
TFS CAPITAL LLC 133,070$2,655,0000.23%
View complete list of TETRAPHASE PHARMACEUTICALS I shareholders